777 related articles for article (PubMed ID: 11465522)
21. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study.
Smith WT; Londborg PD; Glaudin V; Painter JR
Am J Psychiatry; 1998 Oct; 155(10):1339-45. PubMed ID: 9766764
[TBL] [Abstract][Full Text] [Related]
22. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression.
Bouwer C; Stein DJ
S Afr Med J; 1997 Apr; 87(4 Suppl):534-7, 540. PubMed ID: 9180827
[TBL] [Abstract][Full Text] [Related]
23. Buspirone augmentation of antidepressant therapy.
Dimitriou EC; Dimitriou CE
J Clin Psychopharmacol; 1998 Dec; 18(6):465-9. PubMed ID: 9864079
[TBL] [Abstract][Full Text] [Related]
24. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention.
Michelson D; Bancroft J; Targum S; Kim Y; Tepner R
Am J Psychiatry; 2000 Feb; 157(2):239-43. PubMed ID: 10671393
[TBL] [Abstract][Full Text] [Related]
25. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.
Brown EB; McElroy SL; Keck PE; Deldar A; Adams DH; Tohen M; Williamson DJ
J Clin Psychiatry; 2006 Jul; 67(7):1025-33. PubMed ID: 16889444
[TBL] [Abstract][Full Text] [Related]
26. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
Shelton RC; Williamson DJ; Corya SA; Sanger TM; Van Campen LE; Case M; Briggs SD; Tollefson GD
J Clin Psychiatry; 2005 Oct; 66(10):1289-97. PubMed ID: 16259543
[TBL] [Abstract][Full Text] [Related]
27. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression.
Lydiard RB; Stahl SM; Hertzman M; Harrison WM
J Clin Psychiatry; 1997 Nov; 58(11):484-91. PubMed ID: 9413414
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
29. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression.
Ravindran AV; Guelfi JD; Lane RM; Cassano GB
J Clin Psychiatry; 2000 Nov; 61(11):821-7. PubMed ID: 11105734
[TBL] [Abstract][Full Text] [Related]
30. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.
Patris M; Bouchard JM; Bougerol T; Charbonnier JF; Chevalier JF; Clerc G; Cyran C; Van Amerongen P; Lemming O; Høpfner Petersen HE
Int Clin Psychopharmacol; 1996 Jun; 11(2):129-36. PubMed ID: 8803650
[TBL] [Abstract][Full Text] [Related]
31. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
[TBL] [Abstract][Full Text] [Related]
32. Fluoxetine versus placebo in posttraumatic stress disorder.
Martenyi F; Brown EB; Zhang H; Prakash A; Koke SC
J Clin Psychiatry; 2002 Mar; 63(3):199-206. PubMed ID: 11926718
[TBL] [Abstract][Full Text] [Related]
33. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline.
Stahl SM
Biol Psychiatry; 2000 Nov; 48(9):894-901. PubMed ID: 11074227
[TBL] [Abstract][Full Text] [Related]
34. Citalopram treatment of fluoxetine-intolerant depressed patients.
Calabrese JR; Londborg PD; Shelton MD; Thase ME
J Clin Psychiatry; 2003 May; 64(5):562-7. PubMed ID: 12755660
[TBL] [Abstract][Full Text] [Related]
35. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group.
Mehtonen OP; Søgaard J; Roponen P; Behnke K
J Clin Psychiatry; 2000 Feb; 61(2):95-100. PubMed ID: 10732656
[TBL] [Abstract][Full Text] [Related]
36. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.
Landén M; Eriksson E; Agren H; Fahlén T
J Clin Psychopharmacol; 1999 Jun; 19(3):268-71. PubMed ID: 10350034
[TBL] [Abstract][Full Text] [Related]
37. Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.
Mowla A; Kardeh E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):970-3. PubMed ID: 21291943
[TBL] [Abstract][Full Text] [Related]
38. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
[TBL] [Abstract][Full Text] [Related]
39. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.
Fava M; Thase ME; DeBattista C
J Clin Psychiatry; 2005 Jan; 66(1):85-93. PubMed ID: 15669893
[TBL] [Abstract][Full Text] [Related]
40. Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.
Tohen M; Case M; Trivedi MH; Thase ME; Burke SJ; Durell TM
J Clin Psychiatry; 2010 Apr; 71(4):451-62. PubMed ID: 20361905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
